Japan Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within Japan and his mission to instill a start-up culture within the Japanese biopharmaceutical industry. “[My mission is] urging universities, biotech start-ups…
USA Helen Stimson, president of the Delaware BioScience Association, discusses Delaware’s attractive cost of living, legal system, interconnectivity, as well as the vital role that the life sciences play within the state. Ms. Stimson, after a distinguished career with Agilent Technologies, you became president of the Delaware BioScience Association just a…
Austria Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis of the vicious cycle associated with establishing generics market share in Austria as well as the inconsistences of government regulations…
Indonesia Darodjatun Sanusi, Executive Director of GP Farmasi (National Association of Local Companies in Indonesia), explains the opportunities and challenges that his members are facing as well as the future directions that the industry should take to further enhance its capabilities and continue its growth. As Executive Director of GP Farmasi,…
Colombia Thomas Voigt, executive president of the German Chamber of Commerce in Colombia for seven years, discusses the gradual decentralisation of business in Colombia and the increasingly long-term commitment of German companies to this market. Can you give us a brief history of German Chamber of Commerce in Colombia? “German companies…
Colombia Cristhian Salamanca, executive director of the Colombia-India Chamber of Commerce and Industry discusses the ties between both countries, the important role of the chamber in attracting Indian companies to Colombia, and the ease of doing business for pharmaceutical companies in the country after obtaining INVIMA approval. Could you please provide…
Colombia Executive president of ACEMI (La Asociación Colombiana de Empresas de Medicina Integral), Jaime Arias, discusses fostering the constructive participation of all actors in the Colombian healthcare sector and the challenges that need to be addressed to develop the sustainability of the healthcare system in the long-term. Could you explain ACEMI’s…
Colombia With over a decade as executive director of the Pharmaceutical Chamber of ANDI (The Colombian National Business Association), Rodrigo Arcila Gomez, shares his optimistic insights on the growth of the sector, the current status of pricing negotiations, his key achievements, and the need for a pharmaceutical landscape built on trust.…
Indonesia Dr. Kuntjoro Adi Purjanto, Chairman of PERSI (National Association of Hospitals in Indonesia), explains the role that public and private hospitals are playing to successfully realize the national healthcare goals and the active collaboration of PERSI with the government to enhance the Indonesian hospital eco-system. Could you please introduce yourself…
Colombia Gustavo Morales, Executive Director of the Association of Pharmaceutical Research and Development Laboratories (AFIDRO) and proud advocate of intellectual property has successfully changed Colombian public opinion on the pharmaceutical industry. In this interview, Gustavo explains how recent regulations will increase the demand of pharmaceutical products as well as the incentives…
Indonesia Herny Prasetya, President of the International Society of Pharmaceutical Engineering (ISPE) in Indonesia highlights the importance of the implementation of global guidelines in Indonesia and wishes to focus on human capital, compliance and local API manufacturing for ISPE’s members. Could you please introduce to our international audience what are the…
Colombia In explaining the role of the Colombia National Food and Drug Surveillance Institute (INVIMA) and its impact on the regulatory landscape of the healthcare sector, Javier Guzman, Executive Director, centres the discussion on four key pillars: institutional strengthening, efficiency, transparency and competitiveness. He speaks about his main priorities, the Colombian…
See our Cookie Privacy Policy Here